Policy field note
Understanding the peptide policy announcement
An independent guide to the documents, the company preview and the questions a reader can still ask.
What changed federally
Federal officials describe conditional section 503A enforcement discretion while the bulk-substance list goes through rulemaking. It concerns state-licensed pharmacies, federal facilities and licensed physicians. The notice describes enforcement intent; it does not permanently list these substances or create a section 503B permission.
On October 29, 2026, the Federal Register listing remained unpublished, with publication scheduled for October 30. The notice calls the policy a nonbinding draft. Its schedule does not establish an effective date, and the document creates no rights for readers or suppliers.
The notice also says compounded medicines lack FDA approval and receive no FDA premarket assessment of safety, effectiveness or quality. Treating the announcement as a product endorsement would go beyond what it says. Nor does it license a pharmacy or demonstrate clinical benefit.
HHS may reconsider its approach if a safety signal or product-quality problem emerges.
Check the preparation
Each peptide’s discretion lasts until a final inclusion/exclusion rule.
Exact preparations
Each row requires every condition.
Scroll horizontally to read both columns on smaller screens.
| Substance form | Administration |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral or topical; not intravenous |
| TB-500 acetate (thymosin beta-4 fragment) | Subcutaneous or intramuscular injection |
| Epitalon acetate | Subcutaneous or intramuscular injection; intermittent courses |
| Semax free base | Intranasal |
| KPV acetate | Oral or topical |
| MOTS-c acetate | Subcutaneous or intramuscular injection |
Read the requirements
- Appendix A substance.
- Match Appendix B’s amino-acid sequence, chemical structure, molecular weight/formula and routes.
- Section-510-registered facility; valid certificate of analysis (COA), Appendix B identity/purity/potency/contaminant tests.
- Original bulk manufacturer: section-510-registered, CGMP/FD&C compliant; physical location on COA. Registered intermediaries document manufacturer and COA validation.
- Report products, serious adverse events regardless of causality, and quality issues to FDA and compounding/destination states. Use MedWatch for events/quality; provide label reporting instructions. Report active-ingredient/strength-per-unit, original manufacturer/facility identifier, dosage form/route.
- Include: “This is a compounded drug product. Not for resale.”
- Only one active pharmaceutical ingredient, from Appendix A.
- For oral formulations, document adequate human oral bioavailability of the formulation supplied.
- Co-packaged/drug-containing delivery devices: FDA-510(k)-cleared syringes only; noninjectable application unresolved.
- Meet other FD&C requirements, including sanitary compounding and patient-specific prescriptions.
Understand the safeguards
Compounding errors can introduce contamination or incorrect strength.
State boards generally oversee state-licensed pharmacies outside 503B; FDA also inspects them and primarily supervises registered 503B outsourcing facilities.
Finished products satisfying 503A conditions are exempt from current good manufacturing practice (CGMP); 503B preparations must comply.
Separate the company’s plan
Hims & Hers announced Peptides+ on October 29 as a preview with a sign-up list for a future launch. The proposed offerings include sermorelin, glutathione, B12, NAD+ and L-carnitine; the group is not exclusively peptides. BPC-157 and TB-500 are later possibilities, contingent on being allowable.
Independent prescribing, licensed pharmacies and ongoing support are parts of the company’s proposed model. Its cautionary statement describes uncertainty around launch timing, availability, manufacturing and clinical outcomes. We did not evaluate an intake, a prescription or a shipment.
The Peptides+ announcement does not establish which GLP-1 medicines Hims or Hers currently offers.
Reader questions
Does the planned menu identify the final product?
No. The announcement does not confirm a particular salt, route, formulation, price or state eligibility. Those details would need their own current evidence.
How should I use the linked reviews?
Read each review within its stated scope, then follow the separate notice to this explainer. We have not refreshed those reviews’ treatment lists, prices or research dates as part of this policy article. Comparing the two pages is a way to identify unanswered questions, rather than an assurance that an offer has been verified.
Assessment
GOV Health Report is a private commercial publication, not a government agency. This article carries no government endorsement. We organized the explanation around the federal document and then the company’s announcement so readers can inspect each on its own terms. The linked reference entries retain their earlier evidence and dates.
Scope and disclosure
AI assisted the drafting and source comparison. No clinician has reviewed this article. Our work used extracted primary-source text; it did not include visual inspection of chemical drawings, a fresh evaluation of the underlying clinical studies, or an audit of a pharmacy, manufacturer or state-law pathway. We make no treatment or dosing recommendation.
Sources
- HHS policy
HHS
- Federal Register notice
Federal Register
- Peptides+ preview
Hims & Hers
- FDA compounding Q&A
FDA